Vanda Pharmaceuticals (VNDA) Reports Q2 Loss Per Share of 1c, Offers Guidance
Get Alerts VNDA Hot Sheet
Price: $4.48 --0%
EPS Growth %: -16.7%
Financial Fact:
Product sales: 38.48M
Today's EPS Names:
WF, CWBC, GLTO, More
EPS Growth %: -16.7%
Financial Fact:
Product sales: 38.48M
Today's EPS Names:
WF, CWBC, GLTO, More
Join SI Premium – FREE
Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q2 EPS of ($0.01), $0.28 better than the analyst estimate of ($0.29). Revenue for the quarter came in at $27.6 million versus the consensus estimate of $24.55 million.
2015 Financial Guidance
Vanda is updating its 2015 financial guidance and expects to achieve the following financial objectives in 2015:
Non-GAAP Operating expenses also excludes:
For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Alphabet stock surges 11% to record high on Q1 earnings beat, first-ever dividend
- Amundi surges as on bigger-than-expected profit, record AUM
- Avantor (AVTR) Tops Q1 EPS by 2c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!